Fintel reports that on November 7, 2023, Citigroup initiated coverage of BridgeBio Pharma (NASDAQ:BBIO) with a Buy recommendation.
Analyst Price Forecast Suggests 70.95% Upside
As of October 31, 2023, the average one-year price target for BridgeBio Pharma is 47.66. The forecasts range from a low of 33.33 to a high of $63.00. The average price target represents an increase of 70.95% from its latest reported closing price of 27.88.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for BridgeBio Pharma is 37MM, an increase of 289.05%. The projected annual non-GAAP EPS is -3.31.
What is the Fund Sentiment?
There are 439 funds or institutions reporting positions in BridgeBio Pharma. This is an increase of 15 owner(s) or 3.54% in the last quarter. Average portfolio weight of all funds dedicated to BBIO is 0.33%, an increase of 12.36%. Total shares owned by institutions increased in the last three months by 1.93% to 158,176K shares. 
The put/call ratio of BBIO is 0.54, indicating a bullish outlook.
What are Other Shareholders Doing?
Kohlberg Kravis Roberts & Co. holds 31,061K shares representing 17.85% ownership of the company. No change in the last quarter.
Viking Global Investors holds 26,621K shares representing 15.30% ownership of the company. No change in the last quarter.
Aisling Capital Management holds 6,068K shares representing 3.49% ownership of the company. No change in the last quarter.
Laurion Capital Management holds 4,749K shares representing 2.73% ownership of the company. In it's prior filing, the firm reported owning 3,513K shares, representing an increase of 26.04%. The firm increased its portfolio allocation in BBIO by 15.33% over the last quarter.
XBI - SPDR(R) S&P(R) Biotech ETF holds 4,481K shares representing 2.58% ownership of the company. In it's prior filing, the firm reported owning 2,485K shares, representing an increase of 44.54%. The firm increased its portfolio allocation in BBIO by 86.17% over the last quarter.
BridgeBio Pharma Background Information
(This description is provided by the company.)
BridgeBio Pharma Inc. is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio's pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
